Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 971 | 139 | 812 |
| Samples | 645 | 101 | 535 |
| Peptides | 493 | 80 | 415 |
Function
PTPRJ · Protein tyrosine phosphatase receptor type J
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling possibly through interfering with the phosphorylation of Phospholipase C Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000418331 | Q12913 | 718 | 488 |
| ENST00000440289 | Q12913-2 | 252 | 178 |
| ENST00000698881 | A0A8V8TP51* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 487 amino-acid changes on canonical ENST00000418331 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPRJ · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPRJ – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 21/133 16% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 30/612 5% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 3/210 1% | 71/1899 4% |
| Other Solid Cancers | 1/94 1% | 54/1515 4% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Germ Cell Tumour | 2/25 8% | 3/169 2% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 33/1390 2% |
| Colorectal Carcinoma | 8/143 6% | 69/3239 2% |
| Neuroendocrine Tumour | 7/154 5% | 9/577 2% |
| Gastric Carcinoma | 0/74 0% | 41/1809 2% |
| Bladder Carcinoma | 1/58 2% | 15/956 2% |
| Cervical Carcinoma | 3/35 9% | 4/422 1% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 11/810 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 10/752 1% |
| Non-Cancerous | 1/104 1% | 10/830 1% |
| Ovarian Carcinoma | 3/109 3% | 10/998 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Hepatocellular Carcinoma | 3/46 7% | 21/2210 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Kidney Carcinoma | 3/85 4% | 15/1862 1% |
| Other Sarcomas | 4/69 6% | 3/699 0% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Glioma | 3/52 6% | 16/2127 1% |
| Head and Neck Carcinoma | 0/85 0% | 14/1574 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 12/1592 1% |
Mutation Distribution
Where PTPRJ is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPRJ were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 971 mutations in PTPRJ
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|